Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|SPLOCK|^MLOCK|$YWFK$&

Merck Earnings: Modest 2027 Expectations, but Growing Pipeline Potential

Merck’s third-quarter sales grew 5%, while non-GAAP EPS fell 3%. Management nudged up the low end of 2026 revenue guidance, now implying 3%-4% revenue growth, and raised non-GAAP EPS guidance to a range of $2.77-$2.82. Shares rose 4% on Oct. 29.

Sponsor Center